anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pilocarpine toxicity is characterized by an exaggeration of its parasympathomimetic effects. These may include: headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors.

The dose-related cardiovascular pharmacologic effects of pilocarpine include hypotension, hypertension, bradycardia, and tachycardia. 

Pilocarpine should be administered with caution to patients with known or suspected cholelithiasis or biliary tract disease.Contractions of the gallbladder or biliary smooth muscle could precipitate complications including cholecystitis, cholangitis, and biliary obstruction. 

Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate renal colic (or "ureteral reflux"), particularly in patients with nephrolithiasis.

Cholinergic agonists may have dose-related central nervous system effects. This should be considered when treating patients with underlying cognitive or psychiatric disturbances.

Hepatic Insufficiency: Based on decreased plasma clearance observed in patients with moderate hepatic impairment, the starting dose in these patients should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild hepatic insufficiency (Child-Pugh score of 5-6) do not require dosage reductions. To date, pharmacokinetic studies in subjects with severe hepatic impairment (Child-Pugh score of 10-15) have not been carried out. The use of pilocarpine in these patients is not recommended.

* According to grading of Trey C, Burns D, and Saunders S. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med. 1966; 274:473-481. 

Reference: Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit. J. Surg. 1973; 60:646-9.
PURPOSE: The promotion of angiogenesis is an effective strategy for skin wound repair. While the transplantation of endothelial cells has shown promise in vascularization, the underlying mechanism remains unclear. Recent studies have suggested that transplanted cells undergo apoptosis in a short period and release apoptotic extracellular vesicles (ApoEVs) that may have therapeutic potential.
METHODS: In this study, we isolated ApoEVs from human umbilical vein endothelial cells (HUVECs) and characterized their properties. In vitro, we assessed the effects of ApoEVs on the proliferation, migration, and differentiation of endothelial cells and fibroblasts. In vivo, we investigated the therapeutic role of ApoEVs-AT in full-thickness skin wounds, evaluating wound closure rate, re-epithelialization, granulation tissue formation, vascularization, scar area, and collagen 3(Col3)/collagen 1(Col 1) ratio.
RESULTS: ApoEVs derived from HUVECs displayed typical characteristics. In vitro, ApoEVs significantly enhanced the proliferation, migration, tube formation, and expression of angiogenic-related genes in endothelial cells and slightly promoted the proliferation and migration of fibroblasts. In vivo, ApoEVs improved the wound closure rate, re-epithelialization, the formation of granulation tissue, and vascularization. Besides, ApoEVs reduced scar formation, accompanied by an increase in the Col 3/ Col 1 ratio.
CONCLUSION: Given their abundant source and effectiveness, this study provided a novel approach for angiogenesis in tissue regeneration and deepened the understanding of from death to regeneration.
DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
983,132. Chewable hematinic tablets. AMERICAN CYANAMID CO. March 13, 1963 [April 6, 1962], No. 9911/63. Heading A5B. Chewable hematinic two-layered tablets comprise two medicaments which are normally incompatible, wherein the first medicament is granulated and compression coated with an inert sugar granulation, the second medicament being granulated and compressed superimposed on one face of the sugarcoated layer. (The term " sugar " as used herein is meant to include any sugar or sugar derivative which is compressible, pleasant tasting and chewable.) Preferably, one layer of the tablet consists of a sugar compressioncoated core containing Vitamin C, and the other consists of a granulation comprising a therapeutic ferrous iron compound or Vitamin B complex. The ferrous iron compound may be ferrous sulphate, fumarate, saccharate, gluconate or lactate. The Vitamin C may be used in the form of free ascorbic acid or the sodium salt thereof. Mannitol is the preferred sugar coating substance. The tablets may optionally include physiologically acceptable wetting agents, dyes and flavours, vitamins other than Vitamin C and minerals. The Figure shows a cross-section of a side-view of a tablet comprising an ascorbic acid core 3 coated with mannitol 1, having compressed thereon a layer of ferrous fumarate 2.
The invention discloses a method, a device and a system for extracting symptom cause from medical texts, and particularly relates to the technical field of natural language processing information extraction. The invention mainly comprises a reading module, an extraction module, a sentence pattern module and a display module. The reading module mainly means that the system reads some medical texts. The extraction module mainly comprises a relation word extraction unit, a symptom extraction unit and a symptom factor extraction unit. The method mainly comprises the following steps: firstly, summarizing part of relation word sets; secondly, constructing sentence patterns through symptoms and relation words to extract symptoms and causes; and then extracting the entity after impurity removal and updating. And finally, evaluating the extraction result, if the number of the entities is increased compared with the existing entities, continuing iteration, and if not, ending. The sentence pattern module mainly constructs a regular expression through a plurality of entities. The display module mainly comprises: a storage unit and an output unit. The invention takes the disclosed unstructured medical texts as a starting point, and finally realizes the accurate extraction of symptom causes in the medical texts.
Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with a poor prognosis. It contains a complex tumor microenvironment (TME) that includes various stromal cell types. Comprehending cellular communications within the TME is difficult due to a lack of research models that can recapitulate human PDAC-TME. Previously, we recapitulated, in part, the PDAC-TME containing a diversity of cancer-associated fibroblasts (CAFs) in vitro. This was done by establishing a PDAC organoid by co-culturing patient-derived cancer cells with human induced pluripotent stem cell (hiPSC)-derived mesenchymal and endothelial cells, which was designated the fused pancreatic cancer organoid (FPCO). We further incorporated macrophages derived from the THP-1 cell line, which are the source of tumor-associated macrophages (TAMs), a major TME component, into FPCO, which was designated M0-FPCO. Bulk RNA sequencing (RNAseq) analysis revealed that macrophages in M0-FPCO (FPCO-Mac) lost their pro-inflammatory features but acquired pro-angiogenic features. Consistently, the formation of an endothelial cell network was enhanced in M0-FPCO. Single-cell RNA-seq (scRNA-seq) analysis revealed that M0-FPCO contained five TAM subpopulations similar to the corresponding TAM in human PDAC tissue in the integrated analysis, including SPP1+-TAM, which has been correlated with tumor angiogenesis and cell proliferation. Focusing on PDAC cells, we found that they could survive longer within the organoid in the presence of TAM. Consistent with the prolonged proliferation and survival of PDAC cells, PDAC subclusters were characterized by proliferative features, such as increased M0-FPCO. Therefore, by establishing a PDAC organoid with macrophages, we recapitulated the diversity of TAMs and identified the role of TAM in endothelial network formation as well as in the modulation of PDAC cell properties. SIGNIFICANCE: PDAC organoids, including macrophages using hiPSC, showed that PDAC-TAM has angiogenic features and contributes to PDAC cell survival.
PCT No. PCT/IT94/00124 Sec. 371 Date Mar. 23, 1995 Sec. 102(e) Date Mar. 23, 1995 PCT Filed Jul. 26, 1994 PCT Pub. No. WO95/03822 PCT Pub. Date Feb. 9, 1995Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis, hypertension and pregnancy's gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.
Abstract A three component system and method for whitening teeth.  The first component is a pre-conditioning mouth rinse comprised of a dilute aqueous solution of acetic acid and N-L-alpha-aspartyl-L-phenylalanine methyl ester.   This component cleanses the pellicle film on the user's teeth and improves the uptake of molecular oxygen by the enamel from the second component which comprises a bleaching gel including hydrogen peroxide.  The preferred concentration of hydrogen peroxide is approximately six percent.  The third component is a polishing and pigmenting cream or paste that includes an abrasive substance and a pigmenting agent.  The abrasive agent is preferably an alumina silicate and the pigmenting agent is preferably titanium dioxide particles.
Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
PURPOSE:To obtain a new compound having both nerve growth factor-like activity and a potentiative action on the nerve growth factor-like activity, useful as an anti-demential medicine or a medicine for cerebral apoplexy sequella, etc. CONSTITUTION:The compound of the formula. This compound can be obtained by culturing, under aerobic conditions in a medium containing various kinds of nutrients, microbes Stachybotrys parvispora-F4708 (FERM P-12660) belonging to deuteromycetes Stachybotrys, a strain separated from the fallen leaves collected at Yoshinocho, Omiya, City, Saitama Prefecture, Japan, followed by putting the cultured product to extraction with an organic solvent and purifying and isolating the extract by e.g. a chromatography. The physicochemical properties of the compound of the formula are as follows: molecular formula, C31H39NO5; molecular weight, 505; solubility, soluble in methanol, ethanol, acetone, sparingly soluble in n-hexane, benzene, insoluble in water; color reaction, positive to H2SO4, I2, FeCl3, negative to ninhydrin; appearance, colorless needles under acidic condition. Medicines containing this compound can be easily administered because this compound is not a protein.
Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m\^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
The extent and consequence of pentamidine accumulation following chronic inhalation therapy are not known. As a result, patients receiving Pentamidine Isethionate should be closely monitored for the development of serious adverse reactions that have occurred in patients receiving parenteral pentamidine, including hypotension, hypogly­cemia, hyperglycemia, hypocalcemia, anemia, thrombocytopenia, leukopenia, hepatic or renal dysfunction, ventricular tachycardia, pancre­atitis, Stevens-Johnson syndrome, hyperkalemia and abnormal ST segment of ECG.

Extrapulmonary infection with P. jiroveci has been reported infrequently. Most, but not all, of the cases have been reported in patients who have a history of PJP. The presence of extrapulmonary pneumocystosis should be considered when evaluating patients with unexplained signs and symptoms. 

Cases of acute pancreatitis have been reported in patients receiving aerosolized pentamidine. Pentamidine Isethionate should be discontinued if signs or symptoms of acute pancreatitis develop.
For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
The invention discloses a monoclonal antibody against multi-serotype extreme drug-resistant acinetobacter baumannii and application thereof, and relates to the technical field of medicines. An acinetobacter baumannii monoclonal antibody comprising: a heavy chain variable region complementarity determining region and a light chain variable region complementarity determining region selected from A1) or A2); a1 Amino acid sequences are respectively shown as SEQ ID NO. 1-3 in the heavy chain variable region CDR 1-3, and amino acid sequences are respectively shown as SEQ ID NO. 4-6 in the light chain variable region CDR1 '-3'; a2 Amino acid sequences are respectively shown as heavy chain variable region CDRs 1-3 shown as SEQ ID NO. 9-11, and amino acid sequences are respectively shown as light chain variable region CDRs 1 '-3' shown as SEQ ID NO. 12-14. The monoclonal antibody can specifically identify acinetobacter baumannii and capsular polysaccharide thereof with various serotypes, and can also improve the pulmonary infection of the acinetobacter baumannii.
In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
A cosmetic composition of oriental medicine for atopic dermatitis is provided to relieve itch and inflammation using mixed herb extracts. A cosmetic composition of oriental medicine for atopic dermatitis comprises propylene glycol or alcohol extract of mixed herb medicine. The mixed herb medicine comprises xanthium strumarium, lonicerae Flos, picrasma quassioides, artemisia capillaris Thunb, and leave of Perilla silokiana in a weight ratio of 1-3:1-3:1-3:1-3:1-3. The xanthium strumarium is propylene glycol extracts. The lonicerae Flos, picrasma quassioides, artemisia capillaris Thunb, and leave of Perilla silokiana is alcohol extract. The composition is used in an external skin preparation for atopic dermatitis or cosmetic material for atopic dermatitis.
To research the role of the NLRP3 inflammasome in Schistosoma japonicum-induced granuloma formation and liver fibrosis. In in vivo tests, BALB/c mice were used. shNLRP3 plasmid based on adeno-associated virus serotype 8 (AAV8-shNLRP3) was injected to block NLRP3 inflammasome via tail vein. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were detected to assess liver injury. H&E staining was used for routine histopathological assessment; Masson's trichrome staining was used to detect fibrous tissues and collagen fibers. Hepatic expression of NLRP3, procaspase-1, bioactive caspase-1, collagen-1, tissue inhibitor of metalloproteinases-1 (TIMP-1), and α-smooth muscle actin (α-SMA) were detected by western blot. Serum levels of IL-1β were detected by enzyme-linked immunosorbent assay (ELISA). The inflammatory cell infiltration and hepatic expression of IL-1β around the granuloma were detected by immunohistochemistry staining. Treatment of S. japonicum infected mice with AAV8-shNLRP3 significantly reduced the hepatic levels of bioactive caspase-1 and IL-1β, as well as circulating IL-1β concentrations, while reducing the amounts of myeloperoxidase (MPO) and F4/80 positive cells around the granuloma. Moreover, collagen deposition, TIMP-1, and α-SMA, which are markers of hepatic stellate cell (HSC) activation, were reduced around the liver granuloma. These findings highlight a therapeutic potential of AAV8-shNLRP3 in schistosomiasis cirrhosis.
Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 30% of people with highly symptomatic post-COVID-19 condition (PCC). It involves several symptoms that limit physical and psychological functions and cause reduced quality of life. Evidence for different treatments of POTS and PCC is limited, and this study aimed to evaluate the feasibility of individually tailored physical exercise. The secondary aim of the study was to evaluate the preliminary effectiveness of this intervention. Twenty-six participants (81% female, median age 41 years) were enrolled and performed individually tailored endurance and strength training, with progression, for twelve weeks. During the intervention period, the participants had weekly support from a physiotherapist. Feasibility was evaluated with good compliance, with 76% adherence to exercise prescription and 96% completing the study protocol. The treatment was safe, and the evaluation methods (questionnaires, physical assessments, and accelerometer monitoring) were judged to be feasible. After the intervention, improvements in symptom burden as well as in psychological and physical functions were observed. In conclusion, future randomized controlled trials can be performed with only minor adjustments and could include questionnaires, physical assessment and accelerometer monitoring, which were demonstrated as feasible by this study.
PURPOSE: The present study aimed to epidemiologically evaluate patients with infectious keratitis following corneal transplantation.
METHODS: This retrospective study analyzed medical records of patients who underwent keratoplasty from March 2014 to March 2022 at a tertiary center. A total of seventy-five patients were evaluated. The data were classified based on culture results, the type of microorganisms involved, treatment requirements, and the type of primary keratoplasty performed.
RESULTS: Seventy-five patients were evaluated in this study, with a mean age of 45.9 years (22-95 years). The mean duration between the first surgery and the incidence of infectious keratitis was 1.43 years, and most cases occurred in the first year (56.2%). Bacterial and fungal keratitis in 2.17%, 1.39%, and 1.26% of cases undergoing penetrating keratoplasty (PK), endothelial keratoplasty (EK), and anterior lamellar keratoplasty (ALK) occurred, respectively. Streptococcus viridans (9.3%) and Staphylococcus aureus (6.6%) had the highest prevalence. Across various smear and culture results (gram-positive, gram-negative, fungal, and negative culture), no significant differences were found in endophthalmitis rates (P = 0.797) and the necessity for tectonic grafts (P = 0.790). Similarly, the choice of surgical method (PK, ALK, EK) showed no significant impact on the need for tectonic grafts (P = 0.45) or the rate of endophthalmitis (P = 0.55).
CONCLUSIONS: The incidence of keratitis after a corneal graft was 1.7%, with Streptococcus viridans and Staphylococcus aureus the most common microorganisms. The rate of endophthalmitis associated with post-keratoplasty keratitis was 0.053%. There was no correlation between the necessity for a tectonic graft or the incidence of endophthalmitis and the type of microorganisms involved.
Provided in the present invention is a novel Lactobacillus sp. strain having -glucosidase activities or the like. According to the present invention, the specific Lactobacillus sp. strain has excellent acid resistance, bile resistance, or adhesion of intestinal epithelial cells, and mostly can reach the human body during the oral administration. The specific Lactobacillus sp. strain can inhibit the proliferation of harmful bacteria inside the intestine in an effective manner, thereby being useful as a probiotic material. In addition, according to the present invention, the specific Lactobacillus sp. strain having various functions such as effects in declining blood cholesterol or the like, thereby being used as an ingredient of foods and drugs useful for preventing, alleviating, or treating diseases such as obesity, hyperlipidemia, arteriosclerosis, or lipid-associated metabolic syndrome.
Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
PURPOSE: To describe the progression from outer retinal neovascularization (ORNV) to exudative subretinal new vessels (SRNVs) in idiopathic macular telangiectasia type 2.
METHODS: A total of 135 patients (270 eyes) imaged with optical coherence tomography angiography were included.
MAIN OUTCOME MEASURES: Ellipsoid zone loss, outer retinal hyperreflectivity, ORNV, and SRNVs. Outer retinal neovascularization was defined as a flow signal passing through the outer plexiform layer, with or without vertical linear outer retinal hyperreflectivity on the optical coherence tomography B-scan. Subretinal new vessels were defined as an abnormal capillary network with a peripheral anastomotic arcade seen on en face optical coherence tomography angiography and a convex hyperreflectivity at the retinal pigment epithelium.
RESULTS: Subretinal new vessels were observed in 38/270 eyes (14%). Subretinal new vessels were at a fibrotic stage in 24/38 eyes and at an exudative stage in 6/38 eyes, and a progression from ORNV to SRNVs was documented in 8/38 eyes. All cases showed an ellipsoid zone loss. In seven eyes (2.5%), SRNVs were also associated with subepithelial neovascularization. No retinochoroidal anastomosis was detected. The visual acuity dropped when SRNVs were present.
CONCLUSION: In this case series, SRNVs were found in 14% of eyes. In all cases, they were associated with an ellipsoid zone loss and with outer retinal hyperreflectivity. A progression from ORNV to SRNVs was observed.